These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 22653837

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells.
    Yamaguchi T, Reif GA, Calvet JP, Wallace DP.
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F944-51. PubMed ID: 20810616
    [Abstract] [Full Text] [Related]

  • 3. ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice.
    Spirli C, Okolicsanyi S, Fiorotto R, Fabris L, Cadamuro M, Lecchi S, Tian X, Somlo S, Strazzabosco M.
    Gastroenterology; 2010 Jan; 138(1):360-371.e7. PubMed ID: 19766642
    [Abstract] [Full Text] [Related]

  • 4. Altered store operated calcium entry increases cyclic 3',5'-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective cholangiocytes.
    Spirli C, Locatelli L, Fiorotto R, Morell CM, Fabris L, Pozzan T, Strazzabosco M.
    Hepatology; 2012 Mar; 55(3):856-68. PubMed ID: 21987453
    [Abstract] [Full Text] [Related]

  • 5. Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease.
    Spirli C, Mariotti V, Villani A, Fabris L, Fiorotto R, Strazzabosco M.
    J Hepatol; 2017 Mar; 66(3):571-580. PubMed ID: 27826057
    [Abstract] [Full Text] [Related]

  • 6. Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice.
    Spirli C, Okolicsanyi S, Fiorotto R, Fabris L, Cadamuro M, Lecchi S, Tian X, Somlo S, Strazzabosco M.
    Hepatology; 2010 May; 51(5):1778-88. PubMed ID: 20131403
    [Abstract] [Full Text] [Related]

  • 7. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
    Ambrosini G, Cheema HS, Seelman S, Teed A, Sambol EB, Singer S, Schwartz GK.
    Mol Cancer Ther; 2008 Apr; 7(4):890-6. PubMed ID: 18413802
    [Abstract] [Full Text] [Related]

  • 8. Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys.
    Yamaguchi T, Nagao S, Wallace DP, Belibi FA, Cowley BD, Pelling JC, Grantham JJ.
    Kidney Int; 2003 Jun; 63(6):1983-94. PubMed ID: 12753285
    [Abstract] [Full Text] [Related]

  • 9. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
    Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, Evers BM.
    Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
    [Abstract] [Full Text] [Related]

  • 10. Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways.
    Wei G, Wang M, Carr BI.
    J Cell Physiol; 2010 Jul; 224(1):112-9. PubMed ID: 20301194
    [Abstract] [Full Text] [Related]

  • 11. c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition.
    Carr BI, Wang Z, Wang M, Cavallini A, D'Alessandro R, Refolo MG.
    Cancer Biol Ther; 2011 Sep 15; 12(6):531-8. PubMed ID: 21734462
    [Abstract] [Full Text] [Related]

  • 12. Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype.
    Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP.
    J Biol Chem; 2004 Sep 24; 279(39):40419-30. PubMed ID: 15263001
    [Abstract] [Full Text] [Related]

  • 13. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Evers BM.
    J Surg Res; 2012 Aug 24; 176(2):542-8. PubMed ID: 22261591
    [Abstract] [Full Text] [Related]

  • 14. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
    Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA.
    Cancer Res; 2004 Oct 01; 64(19):7099-109. PubMed ID: 15466206
    [Abstract] [Full Text] [Related]

  • 15. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P, Arienti C, Amadori D, Fabbri F, Carloni S, Tesei A, Vannini I, Silvestrini R, Zoli W.
    J Cell Physiol; 2009 Jul 01; 220(1):214-21. PubMed ID: 19288493
    [Abstract] [Full Text] [Related]

  • 16. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
    Takezawa K, Okamoto I, Yonesaka K, Hatashita E, Yamada Y, Fukuoka M, Nakagawa K.
    Cancer Res; 2009 Aug 15; 69(16):6515-21. PubMed ID: 19638574
    [Abstract] [Full Text] [Related]

  • 17. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
    Wei G, Wang M, Hyslop T, Wang Z, Carr BI.
    Int J Cancer; 2010 Dec 15; 127(12):2949-58. PubMed ID: 21351273
    [Abstract] [Full Text] [Related]

  • 18. Renal activation of extracellular signal-regulated kinase in rats with autosomal-dominant polycystic kidney disease.
    Nagao S, Yamaguchi T, Kusaka M, Maser RL, Takahashi H, Cowley BD, Grantham JJ.
    Kidney Int; 2003 Feb 15; 63(2):427-37. PubMed ID: 12631108
    [Abstract] [Full Text] [Related]

  • 19. Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1).
    Fecteau JF, Bharati IS, O'Hayre M, Handel TM, Kipps TJ, Messmer D.
    Mol Med; 2012 Feb 10; 18(1):19-28. PubMed ID: 21979753
    [Abstract] [Full Text] [Related]

  • 20. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
    Lee MH, Lee SE, Kim DW, Ryu MJ, Kim SJ, Kim SJ, Kim YK, Park JH, Kweon GR, Kim JM, Lee JU, De Falco V, Jo YS, Shong M.
    J Clin Endocrinol Metab; 2011 Jan 10; 96(1):E19-30. PubMed ID: 20926530
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.